June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Multifunctional small molecule TLR4 antagonist for treating ocular neovascularization
Author Affiliations & Notes
  • Suchismita Acharya
    North Tx Eye Research Institute, UNT health Science Center, Fort Worth, Texas, United States
    AyuVis Research LLC, Dallas, Texas, United States
  • Santosh K Panda
    AyuVis Research LLC, Dallas, Texas, United States
  • Jiyang Cai
    Ophthalmology, University of Texas Medical Branch, Galveston, Texas, United States
  • Dorota L Stankowska
    North Tx Eye Research Institute, UNT health Science Center, Fort Worth, Texas, United States
  • Footnotes
    Commercial Relationships   Suchismita Acharya, AyuVis Research (F), AyuVis Research (E), AyuVis Research (P); Santosh Panda, AyuVis Research (P); Jiyang Cai, None; Dorota Stankowska, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 201. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Suchismita Acharya, Santosh K Panda, Jiyang Cai, Dorota L Stankowska; Multifunctional small molecule TLR4 antagonist for treating ocular neovascularization. Invest. Ophthalmol. Vis. Sci. 2017;58(8):201.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The multifactorial pathological challenge of ocular neovascularization is difficult to address so far only by anti-VEGF therapy. We have tested our hypothesis that, a novel class of natural product derived compound with toll like receptor 4 (TLR4) antagonist activity can ameliorate the hyper-inflammation produced by macrophage/macroglia over activation as well as decrease choroidal neovascularization (CNV) size in mice.

Methods : Inhibition of cytokines: Mouse bone marrow derived macrophages were treated with high mobility group box1 (HMGB1, 100 ng/mL), an endogenous TLR4 ligand for 8 hours, with or without 100 mg/mL of test compounds. The mRNA levels of TNF-a, iNOS were measured by real-time RT-PCR, and normalized to the control cells. Inhibition of VEGF production: ARPE-19 cells were treated either with 100ng/mL or without HMGB1 along with the compounds (50µg/mL) for 24 h. Supernatants were collected and assayed using human VEGF ELISA kit according to manufacturer’s instructions. Experiments were repeated three times and one way ANOVA was used for statistical analysis. Inhibition of CNV: Laser CNV was induced in C57BL/6 mice (male, 10-12 weeks, n = 5). Each eye received 4 laser burns. The compounds (200 µg/mL) or BSS (vehicle) were administered by IP injection once before and once daily up to 10 days following laser injury. Fundus fluorescein angiography and optical coherence tomography was used to visualize the CNV lesions. RPE/choroid/sclera flat mounts were prepared and stained with both FITC-conjugated isolectin B4 and anti-ICAM-2 antibody to quantitatively measure the size of CNV lesion.

Results : Compound treatment significantly (p<0.05) decreased TNF-a, iNOS level in macrophages compared to HMGB1 (control). Compound C-Heptaose significantly decrease the production of VEGF (118.75±8.18ng/mL) in ARPE-19 cells as compared to HMGB1 (185.42±18.5 ng/mL) and was comparable to untreated control (108.04±16.15 ng/mL). Intraperitoneal injections of C-Heptaose reduced the average size of CNV lesions to about 50% (p<0.05, n = 2) of those in control mice treated with vehicle only in the mouse model.

Conclusions : Our results are consistent with our hypothesis that this novel class of compounds will decrease inflammation and neovascularization. Further structure optimization of the lead compound and TLR4 dependent and independent mechanistic investigation are underway.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×